期刊文献+

氯氮平治疗帕金森病患者中左旋多巴诱导的异动症 被引量:3

Suppression of Levodopa-induced Dyskinesia in Parkinson's Disease
原文传递
导出
摘要 目的 :探讨氯氮平治疗帕金森病 (PD)患者中左旋多巴诱导的异动症 (LID)的疗效、合适剂量、不良反应。方法 :对 12例出现LID的PD患者添加氯氮平治疗 ,治疗前后进行UPDRS的异动症评分、运动功能评分和血白细胞的计数。结果 :氯氮平 (5 0± 5 1)mg显著改善了 91 7% (11/12 )PD患者的异动症状 ,治疗前异动症评分为 3 4± 0 7,治疗后为 1 6± 1 3 ,差异显著 (P <0 0 1)。治疗过程中无患者出现运动功能的恶化和血白细胞的减少。结论 :小剂量 (5 0mg)氯氮平能有效改善PD患者的LID 。 Aim:To evaluate the efficacy,optimal doses and side effects of clozapine for treating levodopa induced dyskinesia in parkinsonian patients.Methods:Increasing daily doses of clozapine were given to 12 patients with Parkinson's disease and levodopa induced dyskinesia.The severity of dyskinesia and parkinsonian motor disability were measured respectively by using UPDRS score and WBC counts were moniored before and after the clozapine treatment.Results:Clozapine reduced the levodopa induced dyskinesia in 11 out of 12 patients(91 7%).There is a significant improvement of the dyskinesia after clozapine treatment at daily doses of 50±51 mg,without aggravation of parkinsonian motor disability and changes of WBC counts.Conclusion:Clozapine at daily doses of 50 mg is safely to be used and significantly improves levodopa induced dyskinesia without worsening parkinsonian motor disability.
出处 《中国临床神经科学》 2001年第2期215-216,共2页 Chinese Journal of Clinical Neurosciences
关键词 帕金森病 左旋多巴 异动症 氯氮平 LID Parkinson's disease levodopa dyskinesia
  • 相关文献

参考文献3

二级参考文献10

共引文献128

同被引文献14

  • 1Dorsey ER, Thompson JP, Frasier M, et al. Funding of Parkinson research from industry and US federal and foundation sources. Mov Disord ,2009,24:731-737. 被引量:1
  • 2Marincola FM. Translational medicine: a two-way road. J Transl Med, 2003, l : 1. 被引量:1
  • 3Mankoff SP, Brander C, Ferrone S, et al. Lost in translation : obstacles to translational medicine. J Transl Med, 2004, 2:14. 被引量:1
  • 4Langston JW, Ballard P, Tetrud JW, et al. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science, 1983, 219:979-980. 被引量:1
  • 5Langston JW. MPTP : insights into the etiology of Parkinson ' s disease.. Eur Neurol, 1987, 26 Suppl 1:2-10. 被引量:1
  • 6Morrow GR, Bellg AJ. Behavioral science in translational research and cancer control. Cancer, 1994, 74(4 Suppl ) : 1409-1417. 被引量:1
  • 7Vaillancourt DE, Spraker MB, Prodoehl J, et al. High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. Neurology, 2009, 72:1378-1384. 被引量:1
  • 8Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson' s disease. Science. 1997. 276:2045-2047. 被引量:1
  • 9Waragai M, Sekiyama K, Sekigawa A, et al.α-Synuclein and DJ-1 as Potential Biological Fluid Biomarkers for Parkinson' s Disease. Int J Mol Sci, 2010, 11:4257-4266. 被引量:1
  • 10Hong Z, Shi M, Chung KA, et al. DJ-1 and alpha-synuelein in human cerebrospinal fluid as biomarkers of Parkinson' s disease. Brain, 2010, 133 Pt 3:713-726. 被引量:1

引证文献3

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部